

REPORTED SALES vs. PRIOR PERIOD (\$MM)

	THIRD QUARTER					NINE MONTHS					
	2015	2014	% Change			2015	2014	% Change			
			Reported	Operational ⁽¹⁾	Currency			Reported	Operational ⁽¹⁾	Currency	
NEUROSCIENCE											
US	655	606	8.1%	8.1%	-	2,098	1,807	16.1%	16.1%	-	
Intl	821	965	-14.9%	0.4%	-15.3%	2,560	3,029	-15.5%	-1.1%	-14.4%	
WW	1,476	1,571	-6.0%	3.4%	-9.4%	4,658	4,836	-3.7%	5.3%	-9.0%	
CONCERTA / METHYLPHENIDATE											
US	89	34	*	*	-	317	97	*	*	-	
Intl	89	101	-11.9%	3.9%	-15.8%	291	333	-12.6%	0.9%	-13.5%	
WW	178	135	31.9%	43.7%	-11.8%	608	430	41.4%	51.9%	-10.5%	
INVEGA / PALIPERIDONE											
US	82	89	-7.9%	-7.9%	-	281	264	6.4%	6.4%	-	
Intl	57	67	-14.9%	-0.4%	-14.5%	179	215	-16.7%	-2.1%	-14.6%	
WW	139	156	-10.9%	-4.7%	-6.2%	460	479	-4.0%	2.6%	-6.6%	
INVEGA SUSTENNA / XEPLION / INVEGA TRINZA											
US	277	215	28.8%	28.8%	-	758	599	26.5%	26.5%	-	
Intl	182	188	-3.2%	14.9%	-18.1%	548	571	-4.0%	14.0%	-18.0%	
WW	459	403	13.9%	22.4%	-8.5%	1,306	1,170	11.6%	20.4%	-8.8%	
RISPERDAL CONSTA											
US	103	107	-3.7%	-3.7%	-	306	323	-5.3%	-5.3%	-	
Intl	132	177	-25.4%	-10.6%	-14.8%	430	573	-25.0%	-10.2%	-14.8%	
WW	235	284	-17.3%	-8.1%	-9.2%	736	896	-17.9%	-8.4%	-9.5%	
OTHER NEUROSCIENCE											
US	104	161	-35.4%	-35.4%	-	436	524	-16.8%	-16.8%	-	
Intl	361	432	-16.4%	-2.0%	-14.4%	1,112	1,337	-16.8%	-3.9%	-12.9%	
WW	465	593	-21.6%	-11.2%	-10.4%	1,548	1,861	-16.8%	-7.5%	-9.3%	
ONCOLOGY											
US	394	305	29.2%	29.2%	-	1,090	823	32.4%	32.4%	-	
Intl	776	807	-3.8%	14.3%	-18.1%	2,332	2,422	-3.7%	14.2%	-17.9%	
WW	1,170	1,112	5.2%	18.4%	-13.2%	3,422	3,245	5.5%	18.9%	-13.4%	
IMBRUVICA											
US	98	42	*	*	-	253	81	*	*	-	
Intl	86	14	*	*	**	201	27	*	*	**	
WW	184	56	*	*	**	454	108	*	*	**	
VELCADE											
US	-	-	-	-	-	-	-	-	-	-	
Intl	329	389	-15.4%	0.1%	-15.5%	1,012	1,200	-15.7%	-1.0%	-14.7%	
WW	329	389	-15.4%	0.1%	-15.5%	1,012	1,200	-15.7%	-1.0%	-14.7%	
ZYTIGA											
US	276	252	9.5%	9.5%	-	784	716	9.5%	9.5%	-	
Intl	272	316	-13.9%	3.4%	-17.3%	866	926	-6.5%	12.2%	-18.7%	
WW	548	568	-3.5%	6.1%	-9.6%	1,650	1,642	0.5%	11.0%	-10.5%	
OTHER ONCOLOGY											
US	20	11	81.8%	81.8%	-	53	26	*	*	-	
Intl	89	88	1.1%	19.3%	-18.2%	253	269	-5.9%	11.5%	-17.4%	
WW	109	99	10.1%	26.2%	-16.1%	306	295	3.7%	19.5%	-15.8%	
CARDIOVASCULAR / METABOLISM / OTHER ⁽⁵⁾											
US	1,171	950	23.3%	23.3%	-	3,522	2,603	35.3%	35.3%	-	
Intl	415	472	-12.1%	1.8%	-13.9%	1,278	1,492	-14.3%	-1.9%	-12.4%	
WW	1,586	1,422	11.5%	16.1%	-4.6%	4,800	4,095	17.2%	21.7%	-4.5%	
XARELTO											
US	461	414	11.4%	11.4%	-	1,374	1,094	25.6%	25.6%	-	
Intl	-	-	-	-	-	-	-	-	-	-	
WW	461	414	11.4%	11.4%	-	1,374	1,094	25.6%	25.6%	-	
INVOKANA / INVOKAMET											
US	322	169	90.5%	90.5%	-	890	376	*	*	-	
Intl	18	5	*	*	**	46	9	*	*	**	
WW	340	174	95.4%	97.3%	-1.9%	936	385	*	*	**	
PROCRIT / EPREX											
US	177	184	-3.8%	-3.8%	-	519	538	-3.5%	-3.5%	-	
Intl	86	123	-30.1%	-17.1%	-13.0%	289	398	-27.4%	-14.4%	-13.0%	
WW	263	307	-14.3%	-9.1%	-5.2%	808	936	-13.7%	-8.2%	-5.5%	
OTHER											
US	211	183	15.3%	15.3%	-	739	595	24.2%	24.2%	-	
Intl	311	344	-9.6%	3.8%	-13.4%	943	1,085	-13.1%	-1.5%	-11.6%	
WW	522	527	-0.9%	7.9%	-8.8%	1,682	1,680	0.1%	7.6%	-7.5%	
TOTAL PHARMACEUTICAL											
US	4,509	4,723	-4.5%	-4.5%	-	13,423	13,076	2.7%	2.7%	-	
Intl	3,185	3,584	-11.1%	5.5%	-16.6%	9,943	11,238	-11.5%	4.3%	-15.8%	
WW	\$ 7,694	\$ 8,307	-7.4%	-0.3%	-7.1%	\$ 23,366	\$ 24,314	-3.9%	3.4%	-7.3%	

See footnotes at end of schedule

